指南与共识消化道肿瘤放疗姑息放疗与转移瘤

美国镭学会直肠腺癌非手术治疗适宜使用标准执行摘要:系统综述与指南

Executive Summary of the American Radium Society on Appropriate Use Criteria for Nonoperative Management of Rectal Adenocarcinoma: Systematic Review and Guidelines.
指南 / 共识 · Int J Radiat Oncol Biol Phys · 2024-05-25

美国镭学会基于Cochrane与PRISMA方法检索2012年1月1日至2023年6月15日Ovid Medline数据库,纳入197篇文章,经改良德尔菲法专家小组对6个临床场景的治疗适宜性进行评分。指南强烈推荐对全直肠系膜切除将导致永久性结肠造口或排便控制不佳的直肠癌患者采用非手术治疗(NOM),并推荐在放化疗后约8至12周进行再分期评估肿瘤反应。

要点

  • 对全直肠系膜切除将导致永久性结肠造口或排便控制不佳者,强烈推荐非手术治疗为通常适宜。
  • 放化疗后约8至12周再分期评估肿瘤反应被视为非手术治疗的必要组成部分。
  • 非手术治疗背景下推荐54至56 Gy分27至31次同步化疗后行巩固化疗。

核心结论

  • 越来越多数据显示非手术治疗和原发手术相比三联治疗可带来生活质量获益而不损害肿瘤学结局。
  • 近期数据支持非手术治疗和原发手术应作为重要选择提供给符合条件的患者。
  • 鉴于多学科管理的复杂性,患者应在多学科环境中讨论,治疗应根据个体患者目标与价值观进行定制。

研究设计与样本

  • 采用Cochrane与PRISMA方法检索2012年1月1日至2023年6月15日Ovid Medline数据库中质量足够的前瞻性与回顾性试验及Meta分析。
  • 检索过程产生197篇文章供投票,专家小组通过改良德尔菲共识方法对6个临床场景中各种治疗的适宜性进行评分。

主要发现

  • 检索过程产生197篇文章供投票。
  • 越来越多数据显示非手术治疗和原发手术相比三联治疗可带来生活质量获益而不损害肿瘤学结局。

关键数值与推荐

  • 对全直肠系膜切除将导致永久性结肠造口或排便控制不佳的直肠癌患者,强烈推荐非手术治疗为通常适宜。
  • 放化疗后约8至12周再分期评估肿瘤反应被视为非手术治疗的必要组成部分。
  • 专家小组推荐在接近完全缓解或完全缓解情况下进行主动监测。
  • 非手术治疗背景下推荐54至56 Gy分27至31次同步化疗后行巩固化疗。
  • 对可行低位前切除且肠道功能足够的T3N0高位直肠肿瘤,专家小组强烈推荐原发手术为通常适宜,N+时考虑辅助化疗。

临床怎么用

  • 对全直肠系膜切除将导致永久性结肠造口或排便控制不佳的直肠癌患者,强烈推荐非手术治疗为通常适宜。
  • 放化疗后约8至12周再分期评估肿瘤反应被视为非手术治疗的必要组成部分。
  • 专家小组推荐在接近完全缓解或完全缓解情况下进行主动监测。
  • 非手术治疗背景下推荐54至56 Gy分27至31次同步化疗后行巩固化疗。
  • 对可行低位前切除且肠道功能足够的T3N0高位直肠肿瘤,专家小组强烈推荐原发手术为通常适宜,N+时考虑辅助化疗。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

For patients with rectal cancer, the standard approach of chemotherapy, radiation therapy, and surgery (trimodality therapy) is associated with significant long-term toxicity and/or colostomy for most patients. Patient options focused on quality of life (QOL) have dramatically improved, but there remains limited guidance regarding comparative effectiveness. This systematic review and associated guidelines evaluate how various treatment strategies compare to each other in terms of oncologic outcomes and QOL. Cochrane and Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) methodology were used to search for prospective and retrospective trials and meta-analyses of adequate quality within the Ovid Medline database between January 1, 2012, and June 15, 2023. These studies informed the expert panel, which rated the appropriateness of various treatments in 6 clinical scenarios through a well-established consensus methodology (modified Delphi). The search process yielded 197 articles that advised voting. Increasing data have shown that nonoperative management (NOM) and primary surgery result in QOL benefits noted over trimodality therapy without detriment to oncologic outcomes. For patients with rectal cancer for whom total mesorectal excision would result in permanent colostomy or inadequate bowel continence, NOM was strongly recommended as usually appropriate. Restaging with tumor response assessment approximately 8 to 12 weeks after completion of radiation therapy/chemoradiation therapy was deemed a necessary component of NOM. The panel recommended active surveillance in the setting of a near-complete or complete response. In the setting of NOM, 54 to 56 Gy in 27 to 31 fractions concurrent with chemotherapy and followed by consolidation chemotherapy was recommended. The panel strongly recommends primary surgery as usually appropriate for a T3N0 high rectal tumor for which low anterior resection and adequate bowel function is possible, with adjuvant chemotherapy considered if N+. Recent data support NOM and primary surgery as important options that should be offered to eligible patients. Considering the complexity of multidisciplinary management, patients should be discussed in a multidisciplinary setting, and therapy should be tailored to individual patient goals/values.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Anker CJ, Tchelebi LT, Selfridge JE, et al. Executive Summary of the American Radium Society on Appropriate Use Criteria for Nonoperative Management of Rectal Adenocarcinoma: Systematic Review and Guidelines. Int J Radiat Oncol Biol Phys. 2024. PMID: 38797496. doi:10.1016/j.ijrobp.2024.05.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。